Proton therapy training offered

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Students at Ivy Tech Community College-Bloomington will be the first in the nation to be offered a specialized training program in proton therapy.

BLOOMINGTON, Indiana-Students at Ivy Tech Community College-Bloomington will be the first in the nation to be offered a specialized training program in proton therapy. The college has formed a partnership with ProCure Treatment Centers, Inc. to develop a certificate program that will train and credential students enrolled in the College’s Radiation Therapy program, with courses beginning next fall.

Everything but the protons


Procure’s Training and Development Center, located in Bloomington, celebrated its grand opening on March 27. The 20,000-square-foot center is the first facility in the world dedicated to proton therapy training, ProCure said in a media release. The facility offers before-the-job training that simulates all aspects of proton therapy in a replica of a proton therapy treatment center featuring everything but the actual protons.

Headquartered in Bloomington, ProCure Treatment Centers, Inc. was founded in 2005 by John Cameron, PhD, a particle therapy physics pioneer who was pivotal in the development of the Midwest Proton Therapy Institute in Bloomington. ProCure provides management support and a model for the complete design, construction, operation, and maintenance of proton centers.

Recent Videos
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
1 expert is featured in this series.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
Related Content